Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06588530 · ClinicalTrials.gov registry record · Phase 4
PFAS Exposure and Immune Response to Vaccination in Adults
A Phase 4 study of Diphtheria and Tetanus, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06588530 is a Phase 4 study of Diphtheria and Tetanus that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 20 participants, below the 1,865-participant average among 15 other Diphtheria trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06588530, a Phase 4 study of Diphtheria and Tetanus, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial aims to investigate how exposure to Perfluorononanoic acid (PFNA), a type of per- and polyfluoroalkyl substance (PFAS), affects the immune response to the standard tetanus and diphtheria (Td) vaccine. The study focuses on participants from a community with known prior PFNA exposure through contaminated drinking water. The main question it aims to answer is: * Does exposure to PFNA weaken the body's initial immune response, leading to lower levels of protective antibodies after vaccination? Participants will: * Receive Tetanus and Diphtheria (Td) booster vaccination * Visit the study office 7 times over a 30-day period * Have blood and saliva collected at each study visit
Conditions Studied
Interventions
- BIOLOGICAL TENIVAC
Study Locations (1)
New Jersey
- EOHSI Paulsboro Office - Paulsboro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-11-04 |
| Est. Completion | 2025-01-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06588530
The ClinicalTrials.gov registry entry for NCT06588530 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,865-participant average among 15 other Diphtheria trials with a reported enrollment target (99% lower). The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Diphtheria appearing as the primary indexed condition, and to 1 intervention - of which TENIVAC is the first listed.
NCT06588530 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT06588530 about?
NCT06588530 is a clinical study titled "PFAS Exposure and Immune Response to Vaccination in Adults". This clinical trial aims to investigate how exposure to Perfluorononanoic acid (PFNA), a type of per- and polyfluoroalkyl substance (PFAS), affects the immune response to the standard tetanus and diphtheria (Td) vaccine. The study focuses on participants from a community with known prior PFNA exposu...
What is the current status of trial NCT06588530?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2024-11-04. Estimated completion is 2025-01-08.
What conditions does trial NCT06588530 study?
This clinical trial studies the following conditions: Diphtheria, Tetanus, Environmental Exposure, Vaccination, Adult.
What interventions are being tested in trial NCT06588530?
The interventions under investigation include: TENIVAC (BIOLOGICAL).
Who is sponsoring clinical trial NCT06588530?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06588530 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diphtheria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®
COMPLETED · Phase 4
-
US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease
COMPLETED · Phase 4
-
Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents
COMPLETED · Phase 4
-
Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™
COMPLETED · Phase 4
-
Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine
COMPLETED · Phase 4
-
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.